Trials / Completed
CompletedNCT00547560
Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population
An Ascending Multiple Dose Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of GSI-953 Administered Orally To Healthy Elderly Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
To assess the safety and tolerability of ascending, multiple, oral doses of GSI-953 in healthy elderly subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSI-953 | Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2007-10-22
- Last updated
- 2011-04-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00547560. Inclusion in this directory is not an endorsement.